{"id":11785,"date":"2017-12-13T14:42:42","date_gmt":"2017-12-13T13:42:42","guid":{"rendered":"http:\/\/semmelweis.hu\/english\/?p=11785"},"modified":"2017-12-15T14:43:29","modified_gmt":"2017-12-15T13:43:29","slug":"sir-ravinder-n-maini-famous-for-the-development-of-biological-therapies-has-been-awarded-semmelweis-budapest-award-in-2017-video","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/english\/2017\/12\/sir-ravinder-n-maini-famous-for-the-development-of-biological-therapies-has-been-awarded-semmelweis-budapest-award-in-2017-video\/","title":{"rendered":"Sir Ravinder N. Maini, famous for the development of biological therapies, has been awarded Semmelweis Budapest Award in 2017 (VIDEO)"},"content":{"rendered":"

Sir Ravinder N. Maini, Professor Emeritus of Imperial College in London, Visiting Lecturer of Oxford University has been awarded Semmelweis Budapest Award in 2017. The scientist was awarded the most prestigious international scientific recognition of Semmelweis University for the development of biological therapies that revolutionized the treatment of inflammatory diseases. During the ceremony, Sir Ravinder N. Maini held his lecture entitled \u201cThe development of monoclonal anti-TNF therapy in favour of an efficient treatment\u201d.<\/p>\n

\"\"<\/a>Dr. \u00c1goston Sz\u00e9l, Rector opened the scientific meeting organized on the occasion of the award ceremony and he announced that the awardee of this year\u2019s Semmelweis Budapest Award was Sir Ravinder N. Maini. The nomination of the professor was uniquely supported by the Senate of Semmelweis University. Rector Sz\u00e9l reminded the audience that this award was founded in 2009 and can be awarded to such internationally renowned scientists working in the area of natural science, whose achievements provide new perspectives for the recognition of living nature and serve the benefit of mankind.<\/p>\n

\"\"<\/a>Rector Sz\u00e9l highlighted that Professor Maini\u2019s scientific activities are connected to Budapest and the Hungarian scientific scene in many respects. The Kennedy Institute of Rheumatology, of which Professor Maini was the Director earlier, provided several Hungarian researchers with scholarships and therefore enabled them to learn first-hand more about the new therapy solutions of inflammatory diseases. Sir Ravinder Maini has been in Budapest before: he was the guest of honour of Semmelweis Symposium in 2013.<\/p>\n

In the laudation about Sir Ravinder Maini, Rector Sz\u00e9l said that Professor Maini can be considered as the so called \u201cfather\u201d of biological therapies, since he applied antibody in human therapy for the very first time. His outstanding research results greatly contributed to the improvement of the quality of life of patients suffering from rheumatoid arthritis. The TNF (tumor necrosis factor) inhibitor monoclonal antibody (infliximab), which was successfully applied during his researches, was authorized for the treatment of inflammatory diseases in 1998. Furthermore, several other drugs based on the scientific results of Sir Ravinder Maini are in circulation, which are the most important elements of the treatment of rheumatoid arthritis and other inflammatory diseases. Due to his scientific achievements, Sir Ravinder Maini, together with his colleague, Dr. Marc Feldmann has been awarded Lasker Award, which is usually considered as the \u201cantechamber\u201d of the Nobel Prize in the field of medicine.<\/p>\n

\"\"<\/a>Sir Ravinder Maini praised the Hungarian scientific scene as well as the Hungarian researchers with whom he worked together. The professor emphasized that he has strong intellectual and emotional connections with Hungary and the Hungarians. In his lecture he provided a summary about the major stages of his research work started back in 1985 and he also elaborated on the risks that they had to face as well as how they managed to overcome the scepticism of the industry and some of the colleagues.<\/p>\n

\u201cIt was a hard journey indeed, we could not know what to expect in the end, but we were all surprised by the outcome. What causes the utmost pleasure for us is that our discovery provides support for hundred thousands of patients.\u201d, highlighted the researcher.<\/p>\n

 <\/p>\n\n\n